Zacks Equity Research highlights: Whole Foods Market, Inc. (Nasdaq: WFMI) as the Bull of the Day and StanCorp Financial (NYSE: SFG) as the Bear of the Day. In addition, Zacks Equity Research provides analysis Humana, Inc. (NYSE: HUM), Wal-Mart Stores Inc. (NYSE: WMT) and UnitedHealth Group Inc. (NYSE: UNH).
Full analysis of all these stocks is available at http://at.zacks.com/?id=2678.
Here is a synopsis of all five stocks:
Bull of the Day:
Whole Foods Market, Inc. (Nasdaq: WFMI), with a strong brand image, offers investors one of the strongest growth profiles in the industry, and the stock is poised to surge as the demand for natural and organic products improves. The company is also revamping its pricing strategy and concentrating more on value offerings, while maintaining healthy margins.
Stringent cost-control measures, effective inventory management and improved store-level performance are driving earnings growth. The company, in the wake of better-than-expected first-quarter 2011 results, now expects sales growth in a range of 10.7% to 12.8% and a bottom-line increase from 23% to 26% in fiscal 2011.
We have a long-term Outperform recommendation on the stock. Our target price of $70.00, 38.7X 2011 EPS, reflects this view.
Bear of the Day:
We are downgrading StanCorp Financial (NYSE: SFG) to Underperform as we expect delinquencies on commercial mortgage loans to remain modestly high in the foreseeable future. Moreover, we suspect organic growth will remain restricted in the near term, given the sluggish economic environment and challenging labor market conditions.
Also, the earnings results lagged the Zacks Consensus Estimate as well as the year-ago results. Higher premiums in the Insurance Services segment, improved earnings in the Asset Management segment and a positive favorable impact of share buybacks were more than offset by lower favorable claims in the Insurance Services segment.
Our six-month target price of $42.00 equates to 8.4x our earnings estimate for 2011. Combined with the annual dividend of $0.86 per share, this target price implies a negative return of about 7.2% over that period. This is consistent with our Underperform recommendation on the shares.
Latest Posts on the Zacks Analyst Blog:
Humana Upped to Outperform
On the back of strong fourth quarter results, we recently upgraded Humana, Inc. (NYSE: HUM) to Outperform.
The company reported a strong fourth quarter on the heels of improved performance in its operations, lower commercial medical cost trends and surplus cash flow generation in 2010, which also resulted in share buybacks.
Results outshone the Zacks Consensus Estimate by 85 cents.
Humana recently completed the acquisition of Concentra Inc. for $790 million in cash on December 22, 2010. Consequently, Humana expects an increase in its consolidated revenue for 2011.
Concentra produces approximately $800 million of revenues annually from 240 workplace health-care facilities and more than 300 medical centers in 42 states. Moreover, the acquisition will provide access to Humana’s medical members in certain geographical areas.
With the closure of the acquisition of Concentra, Humana had raised its earnings per share guidance for 2011, and sees earnings per share in the range of $5.45–$5.65, from the previous outlook of $5.35–$5.55.
Additionally, Humana’s better-than-expected result was attributable to higher average Medicare Advantage membership, which also increased the revenues from premium and administrative services.
At the end of the fourth quarter, Humana’s Medicare Advantage membership jumped nearly 16.8% from the prior-year quarter. However, the increase was partially offset by lower average medical membership in the stand-alone Prescription Drug Plan (PDP) and commercial fully-insured group plans.
Looking forward, we believe that the Medicare Advantage and PDP membership growth estimates for 2011 are expected to increase on strong sales of 2010. Moreover, this also led to the increase in Humana’s 2011 outlook, coupled with the stand-alone Prescription Drug Plan (PDP) offerings during the recently completed 2011 open enrollment period.
Humana now anticipates EPS for the year ending December 31, 2011 (FY11) in the range of $5.70 to $5.90 versus its previous estimate of $5.45 to $5.65. This increase in FY11 EPS guidance primarily reflects better-than-expected sales for the company’s Medicare Advantage and stand-alone PDP offerings during the recently completed 2011 open enrollment period as well as an increase in expected Commercial Segment earnings.
Further, with the launch of a Medicare Part D PDP in collaboration with Wal-Mart Stores Inc. (NYSE: WMT) on October 1, 2010, Humana will now be able to provide Medicare beneficiaries including seniors and disabled citizens to save more than $450 on average in 2011 on premiums, prescription medication co-payments and cost-shares than the drug plans in 2010.
Apart from this, Humana has surplus cash equivalents and investment securities, which have grown drastically by 18% year over year in 2007 and 26% in both 2008 and 2009, although growth moderated at 10.0% in 2010. The company has utilized its excess cash to repurchase shares or for other corporate purposes.
During 2010, Humana repurchased shares worth $100 million, leaving approximately $150 million that can be repurchased by the end of 2011. Going ahead, the strong cash position and capital leverage should help Humana to add to shareholders’ value and confidence in the stock.
Recently, the U.S. Department of Defense (DoD) has awarded its Tricare contract to Humana to administer health benefits to soldiers and their families in the 10-state South region. However, it was initially awarded to a division of Minnesota-based UnitedHealth Group Inc. (NYSE: UNH), but after continuous protests by Humana, DoD reviewed their decision and awarded the $23.5 billion 5-year contract to Humana on February 25, 2010.
As a result of winning the contract, management further upgraded its earnings guidance for 2011 to reflect the extinguishment of expenses of approximately $0.25 per share, which would have been otherwise incurred for the loss of contract in early 2012. Humana’s 2011 earnings guidance was further raised to $5.95 to $6.15 per share, from previous estimates of $5.70 to $5.90 per share.
The quantitative Zacks #1 Rank (short term Strong Buy rating) on the stock indicates strong upward pressure on the shares over the near term.
Headquartered in Louisville, Kentucky, Humana Inc. is one of the largest health care plan providers in the United States. Humana provides health insurance benefits under Health Maintenance Organization (HMO), Private Fee-For-Service (PFFS) and Preferred Provider Organization (PPO) plans. The company also provides other benefits with specialty products including dental, vision and other supplementary benefits.
Get the full analysis of all these stocks by going to http://at.zacks.com/?id=2649.
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks “Profit from the Pros” e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=7158.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment
Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4582.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/ZacksResearch
Join us on Facebook: http://www.facebook.com/ZacksInvestmentResearch
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
SOURCE Zacks Investment Research, Inc.
Web Site: http://www.zacks.com
Tagged with: (Nasdaq: WFMI) • (NYSE: HUM) • (NYSE: SFG) • (NYSE: UNH) • (NYSE: WMT) • Bulls and Bears • Business • Common stock • Companies • Equity Investing • Humana • Industry • Investing • Investment Research • Markets • Medicare • Medicare Advantage • Mutual Funds • New York Stock Exchange • Preferred stock • Prescription drug • StanCorp Financial Group • Stock market • Stock Picks • UnitedHealth Group • Wal-Mart • Zacks
Filed under: Business